Share on StockTwits
 

Mednax (NYSE:MD) Director Md Carlo A. Waldemar unloaded 10,668 shares of Mednax stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $55.40, for a total value of $591,007.20. Following the transaction, the director now directly owns 5,350 shares of the company’s stock, valued at approximately $296,390. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at KeyCorp initiated coverage on shares of Mednax in a research note to investors on Tuesday, December 17th. They set a “hold” rating on the stock. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $106.57.

Shares of Mednax (NYSE:MD) traded up 1.81% on Monday, hitting $56.30. 713,233 shares of the company’s stock traded hands. Mednax has a 1-year low of $41.825 and a 1-year high of $56.445. The stock’s 50-day moving average is $53.95 and its 200-day moving average is $52.33. The company has a market cap of $5.691 billion and a price-to-earnings ratio of 19.91.

Mednax (NYSE:MD) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.20 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.75 by $0.55. The company had revenue of $567.00 million for the quarter, compared to the consensus estimate of $555.30 million. Analysts expect that Mednax will post $3.15 EPS for the current fiscal year.

MEDNAX, Inc (NYSE:MD) is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.